Exclusive Summary

• Essential for acute inpatient treatment of treatment-resistant depression and OCD, meeting strict clinical needs for rapid onset and non-oral administration.
• Originator patents have long expired; however, stringent sterile parenteral manufacturing barriers make this injection significantly less competitive than oral formulations.
• Empowered by China's API-FDF vertical integration, the product offers aggressive pricing advantages for government tenders while securing high distributor margins.
• Comprehensive CTD registration dossiers and globally audited GMP manufacturing systems are available to support rapid local regulatory approval.